Basic and clinical aspects of BOTOX®

Apostolidis, 2005, Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity, J. Urol., 174, 977, 10.1097/01.ju.0000169481.42259.54 Atassi, 2004, Basic immunological aspects of botulinum toxin therapy, Mov. Disord., 19, S68, 10.1002/mds.20020 Brashear, 2005, Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia, Adv. Ther., 22, 49, 10.1007/BF02850184 Brin, 2008, Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay, Mov. Disord., 23, 1353, 10.1002/mds.22157 Brown, 2008, Xeomin® displays lower potency and is neutralized by anti-BOTOX® antibodies, Toxicon, 51, 9 Chapman, 2007, Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia, Clin. Ther., 29, 1325, 10.1016/j.clinthera.2007.07.020 Dressler, 2006, Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc, Eur. J. Neurol., 13, 11, 10.1111/j.1468-1331.2006.01439.x Fernandez-Salas, 2008, A sensitive and robust western blot cell-based assay to measure the activity of botulinum neurotoxin serotype A, Toxicon, 51, 11 Gimenez, 1970, Studies on strain 84 of Clostridium botulinum, Zentralbl. Bakteriol. [Orig.], 215, 212 Goschel, 1997, Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies – therapeutic consequences, Exp. Neurol., 147, 96, 10.1006/exnr.1997.6580 Hatheway, 1989, Bacterial sources of clostridial neurotoxins, 3 Hunt, 2008, Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test, J. Am. Acad. Dermatol., 58, 517, 10.1016/j.jaad.2007.11.015 Hunt, 2009, Potency evaluation of a formulated drug product containing 150 kD botulinum neurotoxin type A, Clin. Neuropharmacol., 32, 28, 10.1097/WNF.0b013e3181692735 Hunt, 2008, Secondary cleavage of a fluorescently labeled SNAP-25 substrate by Xeomins drug product, Toxicon, 51, 13 Kim, 2004, Blue ocean strategy, Harv. Bus. Rev., 1 Lietzow, 2008, Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis, Protein J., 27, 420, 10.1007/s10930-008-9151-2 Lowe, 2007, Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety, J. Am. Acad. Dermatol., 56, 604, 10.1016/j.jaad.2007.01.009 Mathew, 2005, Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial, Headache, 45, 293, 10.1111/j.1526-4610.2005.05066.x Naumann, 2005, Toxin neutralizing antibody formation with botulinum toxin type A treatment in the treatment of primary axillary hyperhidrosis, Eur. J. Neurol., 12, 255 Naumann, 2003, Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study, Arch. Dermatol., 139, 731, 10.1001/archderm.139.6.731 Pickett, 2008, Counterfeit botulinum toxins, a serious risk to patient safety, Toxicon, 51, 18 Shimizu, 2008, Characterization of time-dependent enzymatic profiles under various liquid conditions for 150kd and 900kd, Toxicon, 51, 21 Silberstein, 2005, Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial, Mayo Clin. Proc., 80, 1126, 10.4065/80.9.1126 Turkel, 2006, Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity, Arch. Phys. Med. Rehabil., 87, 786, 10.1016/j.apmr.2006.02.015 Yablon, 2005, Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders, Neurology, 64, A72 Yablon, 2007, Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials, Clin. Ther., 29, 683, 10.1016/j.clinthera.2007.04.015